Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2012 1
2013 1
2014 2
2015 3
2016 1
2017 1
2019 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial.
Bertrand D, Stouten V, De Cock D, Pazmino S, Doumen M, de Wergifosse I, Joly J, Badot V, Corluy L, Hoffman I, Taelman V, De Knop K, Geens E, Langenaken C, Lenaerts JL, Lenaerts J, Walschot M, Mannaerts J, Westhovens R, Verschueren P. Bertrand D, et al. Among authors: langenaken c. Scand J Rheumatol. 2022 Nov;51(6):470-480. doi: 10.1080/03009742.2021.1955467. Epub 2021 Sep 13. Scand J Rheumatol. 2022. PMID: 34514929 Clinical Trial.
Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Van der Elst K, Meyfroidt S, Westhovens R; CareRA study group. Verschueren P, et al. Among authors: langenaken c. Arthritis Res Ther. 2015 Apr 9;17(1):97. doi: 10.1186/s13075-015-0611-8. Arthritis Res Ther. 2015. PMID: 25889222 Free PMC article. Clinical Trial.
Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery.
Vander Cruyssen B, Muñoz-Gomariz E, Font P, Mulero J, de Vlam K, Boonen A, Vazquez-Mellado J, Flores D, Vastesaeger N, Collantes E; ASPECT-REGISPONSER-RESPONDIA working group. Vander Cruyssen B, et al. Rheumatology (Oxford). 2010 Jan;49(1):73-81. doi: 10.1093/rheumatology/kep174. Epub 2009 Jul 14. Rheumatology (Oxford). 2010. PMID: 19605374
Comparison of the clinical expression of patients with ankylosing spondylitis from Europe and Latin America.
Benegas M, Muñoz-Gomariz E, Font P, Burgos-Vargas R, Chaves J, Palleiro D, Maldonado Cocco J, Gutiérrez M, Sáenz R, Steckmen I, Rillo O, Mulero J, Sampaio-Barros P, Barcelos A, Vander Cruyssen B, Vazquez-Mellado J, Collantes Estevez E; RESPONDIA group; ASPECT study group; REGISPONSER study group. Benegas M, et al. J Rheumatol. 2012 Dec;39(12):2315-20. doi: 10.3899/jrheum.110687. Epub 2012 Nov 12. J Rheumatol. 2012. PMID: 23149388
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R. Verschueren P, et al. Among authors: langenaken c. Ann Rheum Dis. 2015 Jan;74(1):27-34. doi: 10.1136/annrheumdis-2014-205489. Epub 2014 Oct 30. Ann Rheum Dis. 2015. PMID: 25359382 Clinical Trial.
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial.
Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R. Verschueren P, et al. Among authors: langenaken c. Ann Rheum Dis. 2017 Mar;76(3):511-520. doi: 10.1136/annrheumdis-2016-209212. Epub 2016 Jul 18. Ann Rheum Dis. 2017. PMID: 27432356 Clinical Trial.